Amgen CFO reports tax-withholding of 5,748 shares

Amgen Inc. EVP & CFO Peter H. Griffith reported a Form 4 transaction showing a tax-related share disposition.

Rhea-AI Filing Summary

Amgen Inc. EVP & CFO Peter H. Griffith reported a Form 4 transaction showing a tax-related share disposition. On March 16, 2026, 5,748 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations by delivering shares. After this withholding transaction, he directly holds 49,001 shares of common stock. His holdings include 756 Dividend Equivalents granted under Amgen’s equity incentive plan, which are paid out in shares on a one-for-one basis as related restricted stock units vest.

Insider Trade Summary

Exercise Price or Tax Liability: 5,748 shares

Exercise Price or Tax Liability 1 txn

Insider Griffith Peter H.

Role EVP & CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	5,748	$366.21	$2.10M

Holdings After Transaction: Common Stock — 49,001 shares (Direct)

Footnotes (1)

1. F1. These shares include 756 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amgen (AMGN) EVP & CFO Peter H. Griffith report?

Peter H. Griffith reported a tax-related share disposition on Amgen stock. On March 16, 2026, 5,748 shares of Amgen common stock were delivered at $366.21 per share to cover tax liabilities, leaving him with 49,001 directly held shares afterward.

Was the latest Amgen (AMGN) Form 4 a market sale of shares?

No, the Form 4 reflects a tax-withholding disposition, not an open-market sale. 5,748 Amgen common shares were delivered at $366.21 per share to pay tax obligations, a common mechanism when equity awards vest, with 49,001 shares remaining directly held.

How many Amgen (AMGN) shares does Peter H. Griffith hold after this Form 4?

After the reported tax-withholding disposition, Peter H. Griffith directly holds 49,001 shares of Amgen common stock. This figure already reflects the 5,748 shares delivered at $366.21 per share on March 16, 2026 to satisfy tax-related obligations.

At what price were the Amgen (AMGN) shares used for Peter H. Griffith’s tax withholding?

The 5,748 Amgen common shares used to satisfy Peter H. Griffith’s tax obligations were valued at $366.21 per share. This tax-withholding disposition reduced his holdings to 49,001 directly held shares following the March 16, 2026 transaction.

What are Dividend Equivalents (DEs) mentioned in Peter H. Griffith’s Amgen (AMGN) holdings?

Dividend Equivalents are credits tied to unvested restricted stock units under Amgen’s equity incentive plan. Griffith’s holdings include 756 DEs, which are paid out in Amgen common shares on a one-to-one basis as the related restricted stock units vest, plus cash for any fractional amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 08:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffith Peter H.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		F		5,748	D	$366.21	49,001(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 756 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Peter H. Griffith	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)